A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT06153251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT06153251
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Interventions
- BMS-986453 Drug
- Cyclophosphamide Drug
- Fludarabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2024
- Primary completion
- May 1, 2030
- Completion
- May 1, 2030
- Last update posted
- Mar 17, 2026
2024 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | Recruiting |
| UCSF Helen Diller Medical Center at Parnassus Heights | San Francisco | California | 94143 | Recruiting |
| Stanford University Medical Center | Stanford | California | 94305 | Recruiting |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Local Institution - 0008 | Nashville | Tennessee | 37203 | Not yet recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| Swedish Medical Center | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06153251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2026 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06153251 live on ClinicalTrials.gov.